Cedric Hermans/ institutroialbertdeux.be;
Jan Blatný/praguemorning.cz
Apr 1, 2026, 11:46
Cedric Hermans: Revisiting the Role of Factor VIII in Haemophilia A in 2026 on E-Learning Insights
Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels, shared a post on LinkedIn:
“Revisiting the role of FVIII in Haemophilia A in 2026
In this episode, Cedric Hermans sits down with Jan Blatný, Consultant Haematologist at Masaryk University and University Hospital Brno, EHCC and EuroBloodNet Centre, and former EAHAD President (2024–2026), to explore the evolving role of Factor VIII in the management of haemophilia A in 2026.
As new therapies such as emicizumab, rebalancing agents, and gene therapy reshape the treatment landscape, this conversation revisits where FVIII remains essential.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance